PMID- 23702697
OWN - NLM
STAT- MEDLINE
DCOM- 20150521
LR  - 20211021
IS  - 1615-2573 (Electronic)
IS  - 0910-8327 (Linking)
VI  - 29
IP  - 3
DP  - 2014 May
TI  - Therapy with immunoglobulin in patients with acute myocarditis and 
      cardiomyopathy: analysis of leukocyte balance.
PG  - 336-42
LID - 10.1007/s00380-013-0368-4 [doi]
AB  - Intravenous immunoglobulin (IVIG) therapy has been used to treat several 
      autoimmune or inflammatory diseases. We conducted a clinical trial of 
      immunoglobulin therapy for acute myocarditis. The study consisted of two 
      projects: (1) a comparison of prognosis between patients treated with and those 
      not treated with IVIG in a multi-center study; (2) analyses of inflammatory 
      cytokines and blood cell profiles in a substudy. In (1), 15 patients were treated 
      with IVIG (1-2 g/kg, over 2 days), whereas 26 were untreated. There was a 
      statistically significant difference between the survival curves of the patients 
      treated with IVIG and the survival curves of those not treated with IVIG. There 
      was no significant difference between the IVIG-treated and untreated groups in 
      terms of clinical parameters of the acute and chronic phases. In (2), 10 patients 
      were treated with IVIG and 6 were untreated. In both groups, all of the data 
      except for changes in the fraction of lymphocytes and the fraction of monocytes 
      decreased due to the treatment or during the course. In patients in the IVIG 
      group, the percentage of peripheral eosinophils was decreased and the percentage 
      of peripheral monocytes was increased by this treatment when they were compared 
      with the pretreatment data. Therefore, therapy with IVIG seems to be a promising 
      treatment for acute myocarditis given that it improves the clinical course, which 
      may be due to modulation of inflammatory cytokines and the peripheral leukocyte 
      balance.
FAU - Kishimoto, Chiharu
AU  - Kishimoto C
AD  - Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto 
      University, 54 Kawara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan, 
      kkishi@kuhp.kyoto-u.ac.jp.
FAU - Shioji, Keisuke
AU  - Shioji K
FAU - Hashimoto, Tetsuo
AU  - Hashimoto T
FAU - Nonogi, Hiroshi
AU  - Nonogi H
FAU - Lee, Jong-Dae
AU  - Lee JD
FAU - Kato, Shigeru
AU  - Kato S
FAU - Hiramitsu, Shinya
AU  - Hiramitsu S
FAU - Morimoto, Shin-ihiro
AU  - Morimoto SI
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20130524
PL  - Japan
TA  - Heart Vessels
JT  - Heart and vessels
JID - 8511258
RN  - 0 (Biomarkers)
RN  - 0 (Cytokines)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
RN  - 0 (Inflammation Mediators)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers/blood
MH  - Cardiomyopathies/blood/diagnosis/*drug therapy/immunology/mortality
MH  - Cytokines/blood
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Immunologic Factors/*therapeutic use
MH  - Inflammation Mediators/blood
MH  - Japan
MH  - Kaplan-Meier Estimate
MH  - Leukocyte Count
MH  - Leukocytes/*drug effects/immunology/metabolism
MH  - Male
MH  - Middle Aged
MH  - Myocarditis/blood/diagnosis/*drug therapy/immunology/mortality
MH  - Predictive Value of Tests
MH  - Time Factors
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2013/05/25 06:00
MHDA- 2015/05/23 06:00
CRDT- 2013/05/25 06:00
PHST- 2012/12/12 00:00 [received]
PHST- 2013/05/10 00:00 [accepted]
PHST- 2013/05/25 06:00 [entrez]
PHST- 2013/05/25 06:00 [pubmed]
PHST- 2015/05/23 06:00 [medline]
AID - 10.1007/s00380-013-0368-4 [doi]
PST - ppublish
SO  - Heart Vessels. 2014 May;29(3):336-42. doi: 10.1007/s00380-013-0368-4. Epub 2013 
      May 24.